Compare Adaptive Biotechnologies Corp (ADPT) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Microchip Technology Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $19.9 (market cap $3.33B), while Microchip Technology Inc. trades at $85.62 (market cap $45.69B). The key difference: Microchip Technology Inc. is far larger — about 13.7× Adaptive Biotechnologies Corp's market cap, and Microchip Technology Inc. pays a 2.16% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | MCHP | |
|---|---|---|
Market Cap | $3.33B | $45.69B |
Sector | Health | Technology |
52-Week High | $22.37 | $102.97 |
52-Week Low | $10.24 | $49.02 |
Enterprise Value | $3.19B | $50.99B |
Dividend Yield | — | 2.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Microchip Technology (MCHP) trades at $84.15, down 0.58% on the day, with a bearish technical signal but strong analyst support. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.57 exceeding the $0.505 forecast. The company benefits from AI-driven semiconductor demand, aerospace and defense growth, and new product launches like the TimePictra 12 platform. However, 2025 saw a net loss of $500,000 on revenue of $4.40 billion, though 2026 projections indicate a return to profitability with a 4.88% net margin.
MCHP presents a mixed outlook: robust growth catalysts in AI and aerospace contrast with high valuation multiples (P/E of 398.14) and recent profitability challenges. The consensus price target of $115.45 suggests 37% upside, but investors face risks from debt levels and market volatility. The stock's near-term direction hinges on execution of its Q2 2026 earnings and sustained demand in key sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
